Oxpentifylline and cetiedil citrate improve deformability of dehydrated sickle cells.
Erythrocytes from 14 patients with homozygous sickle cell anaemia were treated with the calcium ionophore A23187 to induce loss of cellular potassium and water. The dehydrated cells showed a decrease in filterability (loss of deformability) through pores of 5 micron diameter. Oxpentifylline and cetiedil citrate, which preserve erythrocyte cation and water content, had a significant (p less than 0.01) protective effect against loss of deformability at a concentration of 1 mumol/l. Oxpentifylline showed no adverse effect on the rheology, morphology, or haemolysis of sickle cells at concentrations up to 500 mumol/l. Drugs that act on the erythrocyte membrane to maintain cell hydration are of potential rheological benefit in sickle cell anaemia.
D000755:Anemia, Sickle Cell / Q000097:blood*; D000986:Antisickling Agents / Q000494:pharmacology*; D001381:Azepines / Q000494:pharmacology*; D000001:Calcimycin / Q000037:antagonists & inhibitors; D004305:Dose-Response Relationship, Drug; D004907:Erythrocyte Deformability / Q000187:drug effects; D004913:Erythrocytes, Abnormal / Q000187:drug effects*; D006801:Humans; D010431:Pentoxifylline / Q000494:pharmacology*; D013805:Theobromine / Q000031:analogs & derivatives*
D000986:Antisickling Agents; D001381:Azepines; D000001:Calcimycin; C006955:cetiedil; D013805:Theobromine; D010431:Pentoxifylline